Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.09 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by the rapid onset of widespread inflammation in the lungs. ARDS is thought to be the main cause of respiratory failure in COVID-19 patients. Research is still ongoing to further elucidate the different ARDS subtypes that may exist in COVID-19. It is crucial to find new targets for treatment and support of COVID-19 patients with respiratory failure.
Description: change in oxygen saturation and PaO2/FiO2 ratio by 20% on day 6 compared to baseline values prior to Iloprost initiation.
Measure: change in oxygenation parameters Time: 5 daysDescription: likelihood to require intubation in the cohort treated with Iloprost
Measure: Rates of endotracheal intubation Time: 28 daysDescription: in days in the cohort treated with Iloprost
Measure: Invasive ventilation duration Time: 28 daysDescription: in days in the cohort treated with Iloprost
Measure: ICU length of stay Time: 28 daysDescription: in days in the cohort treated with Iloprost
Measure: Hospital Length of stay Time: 28 daysDescription: likelihood to require proning in the cohort treated with Iloprost
Measure: Rates of proning therapy Time: 28 daysDescription: likelihood to require ECMO cannulation in the cohort treated with Iloprost
Measure: Rates of ECMO cannulation Time: 28 daysDescription: likelihood to die of any cause within 28 days of initial hospital presentation
Measure: Mortality Time: 28 days